Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
Quote | Bionomics Limited (NASDAQ:BNOX)
Last: | $0.9142 |
---|---|
Change Percent: | -0.64% |
Open: | $0.9075 |
Close: | $0.92005 |
High: | $0.932 |
Low: | $0.9075 |
Volume: | 4,543 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | Bionomics Limited (NASDAQ:BNOX)
2024-03-21 07:55:00 ET DENVER, Colo., Mar 21, 2024 ( 247marketnews.com )- Bionomics Limited (NASDAQ: BNOX ) released, this morning, the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder. The full data analysis shows that ATTUNE ...
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continu...
Message Board Posts | Bionomics Limited (NASDAQ:BNOX)
Subject | By | Source | When |
---|---|---|---|
Yes, people loading up expecting much higher prices | Golden Cross | investorshub | 09/08/2023 7:51:24 PM |
$BNOX Accumulation this week @Golden Cross . | jedijazz | investorshub | 09/08/2023 7:21:11 PM |
Would luv to close $2+ | Golden Cross | investorshub | 09/08/2023 6:35:51 PM |
$BNOX $1.96 +7.00% green into powerhour and | jedijazz | investorshub | 09/08/2023 6:27:17 PM |
Major FDA meetings scheduled during Sept. 2023 for $BNOX | jedijazz | investorshub | 09/08/2023 5:04:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Bionomics Limited Company Name:
BNOX Stock Symbol:
NASDAQ Market:
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post...
2024-03-21 07:55:00 ET DENVER, Colo., Mar 21, 2024 ( 247marketnews.com )- Bionomics Limited (NASDAQ: BNOX ) released, this morning, the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder. The full data analysis shows that ATTUNE ...
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continu...